Feed / IDXX

IDEXX Laboratories, Inc.

IDXX

Healthcare · 517.81 -0.9% today

Participation confirmed · construction unavailableMarket checked 1 Oct, 15:55 GMT-4

Market read

IDEXX Laboratories, Inc.'s move is spreading beyond its market group.

The latest filing evidence is available. 6 of 40 group members are active now; 1 filing-linked outsider is moving with the group, and 0 of 0 directly disclosed connections are confirming.

What changed
  • Revenue increased 9.7% versus the comparable filing period.
Company-0.9% todayVolume comparison unavailable
Market group6 of 40 activeSoftware Stocks · inactive
Disclosed network0 of 0 confirmingRelationship data unavailable
What would change this read
  • At least 26 of 40 durable members become active together.
  • Capital-flow agreement rises above 55%.
  • CRM remains aligned with the group in the next market snapshot.

Invalidation: The live read weakens if participation falls to 14 of 40 members or fewer.

Watch this read

Research brief

The story so far

Healthcare · Diagnostics & Research

The latest filing evidence is available. 6 of 40 group members are active now; 1 filing-linked outsider is moving with the group, and 0 of 0 directly disclosed connections are confirming.

Evidence that supports
  • Revenue increased 9.7% versus the comparable filing period.
  • Operating margin improved 1.4 percentage points.
  • Net income increased 15.1% versus the comparable filing period.
Evidence that challenges

No thresholded adverse filing evidence is available yet.

What would clarify the read
  • At least 26 of 40 durable members become active together.
  • Capital-flow agreement rises above 55%.
  • CRM remains aligned with the group in the next market snapshot.

Company research

Understand the business, not just the ticker

As of Oct 2, 2026
Business model and earnings drivers

Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.

Key research questions
  • Which operating variable is changing?
  • Is that change durable, cyclical or one-off?
  • What evidence would disprove the current interpretation?
Annual periods9
Price observations616
Usable filing statements272
Verified relationships2
Evidence supporting the case
  • Latest annual revenue changed +10.4% year over year.
  • Operating margin changed +2.7 percentage points in the latest annual period.
  • Net margin changed +1.8 percentage points in the latest annual period.
  • Operating cash flow covered net income at 1.12x in the latest annual period.
  • Credit and interest rates has repeated favorable evidence across 5 filings.
  • Demand and volume has repeated favorable evidence across 5 filings.
  • Foreign exchange has repeated favorable evidence across 5 filings.
Evidence challenging the case
  • Product pipeline and R&D has repeated adverse evidence across 5 filings.
Questions before a position
  • EV/sales is 30% above the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context

Price as of Oct 1, 2026

517.81
6m-8.3%12m-19.0%24m+1.7%
Annual trajectory

Reported annual revenue and per-share history. This is accounting history, not a forecast.

PeriodRevenueYoYDiluted EPSShare change
2021-12-31$3.2B+18.8%—-0.2%
2022-12-31$3.4B+4.7%—-2.3%
2023-12-31$3.7B+8.7%—-0.7%
2024-12-31$3.9B+6.5%—-0.9%
2025-12-31$4.3B+10.4%—-2.7%

What management says matters

Persistent and emerging business drivers

Credit and interest ratespositive · 5 filings
“The increase in net cash used was primarily due to comparatively less cash provided by net borrowings under our Credit Facility, which were $121.0 million during the current period, compared to $329.0 million in the prior period.”
10-Q · Aug 4, 2026 ↗
Demand and volumepositive · 5 filings
“The increase in revenue was primarily due to higher realized prices and higher volumes, particularly in the Americas and Europe.”
10-Q · Aug 4, 2026 ↗
Foreign exchangepositive · 5 filings
“The following table presents cash flow impacts from changes in operating assets and liabilities, excluding the effects of foreign exchange rate fluctuations: For the Six Months Ended June 30, (in thousands) 2026 2025 Change Accounts receivable $ (82,844) $ (7…”
10-Q · Aug 4, 2026 ↗
Legal and regulatory exposuremixed · 5 filings
“The decrease in cash used for other assets and liabilities was primarily due to a litigation settlement payment in the prior year for approximately $80 million and lower income tax payments in the current period, partially offset by higher annual employee inc…”
10-Q · Aug 4, 2026 ↗

Valuation discipline

Descriptive valuation snapshot

Price/sales 9.7× · EV/sales 9.8×. Comparisons use only industry-matched filing peers.

Scenario scaffold

Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.

Price action

How the market is pricing the story

517.81-0.9% today

Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 1 Oct, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.

Developments

No sourced recent-development timeline yet

Jodie has not returned a relevant primary source or news item for IDXX. This is an evidence-coverage gap, not a conclusion that nothing material happened.

Business and financial condition

Reported financial figures are not available yet

Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.

Latest filing assessment

Fundamentals strengthened in the latest filing

10-Q filed 2026-08-04 against the comparable filing from 2025-08-04.

constructive
OperationsconstructiveEvidence score +3
liquidityneutralEvidence score 0
valuationmixed

Capital and cash conversion

Cash conversion improved

supportive

Capital-spending intensity declined while free-cash-flow margin improved.

Capital spending YoY
-11.7%
Capital spending / revenue
+2.4%
Free-cash-flow margin
+23.6%
FCF margin change
+6.6 pts

Capex, revenue, and operating cash flow are matched to the same reported duration. Reported accounting context, not a forecast or trading recommendation.

What improved

  • Revenue increased 9.7% versus the comparable filing period.
  • Operating margin improved 1.4 percentage points.
  • Net income increased 15.1% versus the comparable filing period.

What weakened

No thresholded deterioration was identified.

Filing receipts

“The increase in the gross profit margin was primarily due to lower per-unit costs from higher sales volumes and higher realized prices, which offset inflationary costs.”

“Sales and marketing expense increased primarily due to higher personnel-related and travel costs, as well as higher costs related to commercial expansion.”

“The increase in gross profit was primarily due to higher revenue and a 600 basis point increase in the gross profit margin.”

Historical filing backfill generated after the original filing window. It is not part of Jodie's live track record.

Business ecosystem

The relationships behind IDXX

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

IDXX is currently a Participant in the organic co-movement group Software Stocks. This group is discovered from market behaviour rather than assigned from an industry taxonomy. No verified filing-linked names are available yet.

Context history

Theme membership history

No durable theme membership has been observed for this name yet.